Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

https://finance.yahoo.com/news/gamida-cell-announces-results-phase-120000408.html

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Phase 3 clinical trial of omidubicel will be presented in an oral session at the Presidential Symposium of the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2021), which is being held virtually March 14–17, 2021.

Details about the presentation are as follows:

Time: Monday, March 15, 2021, at 3:24 p.m. CET (10:24 a.m. EST)
Abstract Number: GS2-7
Title: Results of a Phase III Randomized, Multicenter Study Comparing Omidubicel with Standard Umbilical Cord Blood Transplantation (UCBT) in Patients with High-Risk Hematologic Malignancies Following Myeloablation
Lead Author: Professor Guillermo F. Sanz, M.D., Ph.D.

The abstract will also be featured in a live panel discussion, "EBMT Talks: Live with Best Abstracts," on March 15 at 6:10 p.m. CET (1:10 p.m. EST).